Self-reported antiretroviral therapy in injection drug users

JAMA

Volumn 280, Issue 6, 1998, Pages 544-546

  Celentano, David D ^a   Vlahov, David ^a   Cohn, Sylvia ^a   Shadle, Vera M ^a   Obasanjo, Olugbenga ^a   Moore, Richard D ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; EPIDEMIC; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SELF REPORT; SUBSTANCE ABUSE; UNEMPLOYMENT; UNITED STATES;

EID: 0032511356     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.6.544     Document Type: Article

References (18)

1. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretrovival therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962-1969.
2. Department of Health and Human Services, Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep. 1998;47(RR-5):43-82.
3. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers - are we being naive? J Infect Din. 1997;175:237-245.
4. Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV in blood and lymph nodes after potent antiretroviral therapy. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract LB10.
5. Gulick RM, Mellors JW, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV), and lamivudine (3TC). In: Program and abstracts of the XI International Conference on AIDS; July 7-12,1996; Vancouver, British Columbia. Abstract ThB931.
6. 3. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-27, 1997; Washington, DC. Abstract LB7.
7. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA. 1997;277:145-153.
8. Ho DD. Can HIV be eradicated? In: Program and abstracts of the 4th Conference on Retro viruses and Opportunistic Infections; January 22-27, 1997; Washington, DC. Abstract S1.
9. Freeman RC, Rodriguez GM, French JF. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. AIDS Educ Prev. 1995;8:58-71.
10. Bangsberg D, Tulsky J, Hecht F, Moss A. Protease inhibitors in the homeless. JAMA. 1997;278:63-66.
11. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr. 1991;109:75-100.
12. Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338:1281-1292.
13. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994;20:1412-1416.
14. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS. 1997;11:1665-1670.
15. + IDUs eligible for antiretrovirals: what are the barriers to receiving therapy despite universal access? In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, Ill; February 2, 1998.
16. Schaub AF, Steiner A, Vetter W. Compliance to treatment. Clin Exp Hypertens. 1995;15:1121-1130.
17. Cramer JA, Scheyer RD, Mattson RH. Compliance decline between clinic visits. Arch Intern Med. 1990;150:1509-1510.
18. Kasl SV. Issues in patient adherence to health care regimens. J Hum Stress. 1975;1:5-17.